Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Interest & Investment Income (2016 - 2017)

Historic Interest & Investment Income for Teva Pharmaceutical Industries (TEVJF) over the last 9 years, with Q3 2017 value amounting to $28.7 billion.

  • Teva Pharmaceutical Industries' Interest & Investment Income fell 1838.37% to $28.7 billion in Q3 2017 from the same period last year, while for Sep 2017 it was $28.7 billion, marking a year-over-year decrease of 1838.37%. This contributed to the annual value of $84.0 million for FY2017, which is 9974.8% down from last year.
  • According to the latest figures from Q3 2017, Teva Pharmaceutical Industries' Interest & Investment Income is $28.7 billion, which was down 1838.37% from $28.0 billion recorded in Q2 2017.
  • Teva Pharmaceutical Industries' Interest & Investment Income's 5-year high stood at $35.1 billion during Q3 2016, with a 5-year trough of $848.0 million in Q4 2013.
  • Over the past 5 years, Teva Pharmaceutical Industries' median Interest & Investment Income value was $22.3 billion (recorded in 2013), while the average stood at $15.2 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Interest & Investment Income surged by 258306.07% in 2014 and then tumbled by 9625.99% in 2015.
  • Teva Pharmaceutical Industries' Interest & Investment Income (Quarter) stood at $848.0 million in 2013, then grew by 1.53% to $861.0 million in 2014, then increased by 3.14% to $888.0 million in 2015, then increased by 21.17% to $1.1 billion in 2016, then surged by 2564.59% to $28.7 billion in 2017.
  • Its last three reported values are $28.7 billion in Q3 2017, $28.0 billion for Q2 2017, and $1.0 billion during Q1 2017.